ERBB2 and breast cancer: Emerging data have demonstrated potential synergism in promoting antitumor immunity between HER2 therapies and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) or PD-1/PD-L1 inhibitors in BC patients [116,117].